Results 171 to 180 of about 3,466,843 (390)

Structural and functional characterization of chitinase from carnivorous plant Drosera adelae

open access: yesFEBS Open Bio, EarlyView.
A class I chitinase from the carnivorous plant Drosera adelae was expressed and purified using a yeast system, revealing high enzymatic activity. Structural analyses of the catalytic and chitin‐binding domains identified key tyrosine residues involved in substrate binding, offering insights into the enzyme's adaptation for insect digestion.
Kazunari Yoneda   +7 more
wiley   +1 more source

Peptide Separation by Two-dimensional Chromatography and Electrophoresis

open access: hybrid, 1959
Arnold M. Katz   +2 more
openalex   +1 more source

Open Peptide Chains in alpha-Chymotrypsin. [PDF]

open access: bronze, 1956
Bodil Meedom   +4 more
openalex   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

open access: yesFEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior   +5 more
wiley   +1 more source

BCS1L‐Associated Disease: 5′‐UTR Variant Shifts the Phenotype Towards Axonal Neuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the consequences of a pathogenic missense variant (c.838C>T; p.L280F) and a 5′‐UTR regulatory variant (c.‐122G>T) in BCS1L on disease pathogenesis and to understand how regulatory variants influence disease severity and clinical presentation.
Rotem Orbach   +11 more
wiley   +1 more source

Nucleic acid drugs: recent progress and future perspectives

open access: yesSignal Transduction and Targeted Therapy
High efficacy, selectivity and cellular targeting of therapeutic agents has been an active area of investigation for decades. Currently, most clinically approved therapeutics are small molecules or protein/antibody biologics.
Xiaoyi Sun   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy